title: Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
abstract: Previous studies showed that isocitrate dehydrogenase 1 (IDH1) mutation might be a prognostic biomarker of prognosis in glioblastoma (GBM) patients, but the outcomes were various. A meta-analysis of published studies was carried out to reach a reliable assessment of the association between IDH1 mutation and mortality of GBM patients. Relative risks (RRs) with 95% confidence intervals (95%CIs) were pooled using meta-analysis to assess risk of mortality in patients with IDH1 mutation. A total of 20 studies (3 prospective cohort and 17 retrospective cohort studies) were finally included into the meta-analysis. Meta-analysis of total included studies suggested that GBM patients with IDH1 mutation had decreased risk of mortality compared those patients without IDH1 mutation (RR = 0.43, 95%CI 0.35-0.54, P < 0.001). GBM patients with IDH1 mutation from European countries had also decreased mortality risk compared with those patients without IDH1 mutation (RR = 0.35, 95%CI 0.25-0.49, P < 0.001), but GBM patients with IDH1 mutation from Asians only dad 32% decrease of mortality risk compared with those patients without IDH1 mutation (RR = 0.68, 95%CI 0.49-0.94, P = 0.018). The findings from the meta-analysis provide strong evidence for the association between IDH1 mutation and decreased mortality risk of GBM patients. In addition, there is an obvious difference in the mortality risk of GBM patients with IDH1 mutation between western and eastern countries.
authors: Department of Oncology, First Affiliated Hospital of Jilin University, Changchun, 130021, China.
authors: Yuting
authors: Y
authors: Dai
authors: Department of Neurosurgery, Affiliated Hospital of Beihua University, Jilin, 132011, China.
authors: Xianbin
authors: X
authors: Ning
authors: Affiliated Hospital of Guiyang Medical University, Guiyang, 550039, China.
authors: Guoqian
authors: G
authors: Han
authors: Department of Oncology, First Affiliated Hospital of Jilin University, Changchun, 130021, China. sjwklw@sina.com.
authors: Wei
authors: W
authors: Li
mesh_terms: D001208:Asia / Q000453:epidemiology; D044466:Asian People / Q000235:genetics; D001932:Brain Neoplasms / Q000201:enzymology / Q000208:ethnology / Q000235:genetics* / Q000401:mortality; D005060:Europe / Q000453:epidemiology; D005909:Glioblastoma / Q000201:enzymology / Q000208:ethnology / Q000235:genetics* / Q000401:mortality; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics*; D009656:North America / Q000453:epidemiology; D011379:Prognosis; D012306:Risk; D044465:White People / Q000235:genetics
chemical_list: D009363:Neoplasm Proteins; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human
keywords: Glioblastoma; Isocitrate dehydrogenase 1; Mortality
references: N Engl J Med. 2014 Feb 20;370(8):699-708
references: 24552317
references: J Clin Oncol. 2009 Dec 1;27(34):5743-50
references: 19805672
references: Nature. 2012 Aug 30;488(7413):656-9
references: 22763442
references: Neurology. 2014 Sep 23;83(13):1200-6
references: 25150284
references: Biomed Res Int. 2014;2014:654727
references: 24868540
references: Nat Rev Cancer. 2014 Feb;14(2):92-107
references: 24457416
references: Science. 2008 Sep 26;321(5897):1807-12
references: 18772396
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: J Clin Oncol. 2009 Sep 1;27(25):4150-4
references: 19636000
references: Science. 2014 Jun 20;344(6190):1396-401
references: 24925914
references: AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55
references: 22322613
references: Cell. 2013 Oct 10;155(2):462-77
references: 24120142
references: Br J Cancer. 2012 May 22;106(11):1816-25
references: 22568967
references: Nature. 2012 Feb 15;483(7390):479-83
references: 22343889
references: J Natl Cancer Inst. 2010 Jul 7;102(13):932-41
references: 20513808
references: Neuro Oncol. 2014 Sep;16(9):1263-73
references: 24510240
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: J Neurooncol. 2012 Dec;110(3):325-33
references: 23015095
references: J Neurooncol. 2013 Dec;115(3):333-41
references: 24129546
references: Cancer. 2013 Feb 15;119(4):806-13
references: 23184331
references: PLoS One. 2012;7(1):e30339
references: 22291938
references: Lancet Oncol. 2011 Oct;12(11):1062-70
references: 21868286
references: Acta Neuropathol. 2010 Dec;120(6):707-18
references: 21088844
references: JAMA. 2013 Nov 6;310(17):1842-50
references: 24193082
references: Brain Pathol. 2013 Sep;23(5):565-73
references: 23438035
references: Nature. 2012 Feb 15;483(7390):474-8
references: 22343901
references: Acta Neuropathol. 2010 Apr;119(4):487-94
references: 20127344
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Lancet Oncol. 2014 Aug;15(9):e395-403
references: 25079102
references: Oncotarget. 2014 Mar 30;5(6):1515-25
references: 24722048
references: World J Surg Oncol. 2013 Oct 25;11:284
references: 24160898
references: Cancer. 2013 Feb 15;119(4):814-24
references: 22990979
references: Cancer Sci. 2012 Mar;103(3):587-92
references: 22136423